PHIO
Phio Pharmaceuticals·NASDAQ
--
--(--)
--
--(--)
0.94 / 10
Underperform
PHIO's fundamentals score poorly (0.9/10). Key concerns include a negative interest coverage ratio (-59.7) indicating inability to cover interest expenses, and elevated days sales outstanding (203.09) pointing to slow receivable collection. While year-over-year revenue growth (94.06%) is impressive, it is offset by profitability and liquidity issues, leading to an 'Underperform' fundamental rating.
Analysis Checks(3/4)
Total operating revenue (YoY growth rate %)
Value94.06
Score2/3
Weight-119.73%
1M Return1.11%
Value94.06
Score2/3
Weight-119.73%
1M Return1.11%
Interest coverage ratio (EBIT / Interest expense) (%)
Value-59.72
Score2/3
Weight111.81%
1M Return-1.11%
Value-59.72
Score2/3
Weight111.81%
1M Return-1.11%
Days sales outstanding
Value203.09
Score1/3
Weight154.05%
1M Return-1.57%
Value203.09
Score1/3
Weight154.05%
1M Return-1.57%
Operating revenue (YoY growth rate %)
Value87.09
Score2/3
Weight-46.13%
1M Return0.43%
Value87.09
Score2/3
Weight-46.13%
1M Return0.43%
Total operating revenue (YoY growth rate %)
Value94.06
Score2/3
Weight-119.73%
1M Return1.11%
Value94.06
Score2/3
Weight-119.73%
1M Return1.11%
Days sales outstanding
Value203.09
Score1/3
Weight154.05%
1M Return-1.57%
Value203.09
Score1/3
Weight154.05%
1M Return-1.57%
Interest coverage ratio (EBIT / Interest expense) (%)
Value-59.72
Score2/3
Weight111.81%
1M Return-1.11%
Value-59.72
Score2/3
Weight111.81%
1M Return-1.11%
Operating revenue (YoY growth rate %)
Value87.09
Score2/3
Weight-46.13%
1M Return0.43%
Value87.09
Score2/3
Weight-46.13%
1M Return0.43%
Is PHIO undervalued or overvalued?
- PHIO scores 0.94/10 on fundamentals and holds a Premium valuation at present. Backed by its -86.90% ROE, 0.00% net margin, -1.40 P/E ratio, 1.01 P/B ratio, and 77.86% earnings growth, these metrics solidify its Underperform investment rating.
